Finance

Lists
Why is CRSP down 3,60%?
Dive Deeper
CRSP:NASDAQ
Crispr Therapeutics AG
51,47 $
-3,60%
(-1,92) 1D
12 հոկ, 15:24:14 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRSP...
Open
52,91 $
High
53,21 $
Low
51,40 $
Mkt. cap
4,98 մլրդ
Avg. vol.
1,63 մլն
Volume
669,68 հզր
52-wk high
75,16 $
52-wk low
44,12 $
EPS
-4,76 $
Beta
1,45
Shares outstanding
96,69 մլն
No. of employees
393
Open
52,91 $
High
53,21 $
Low
51,40 $
Mkt. cap
4,98 մլրդ
Avg. vol.
1,63 մլն
Volume
669,68 հզր
52-wk high
75,16 $
52-wk low
44,12 $
EPS
-4,76 $
Beta
1,45
Shares outstanding
96,69 մլն
No. of employees
393
News stories
From web sources and news partners
Profile
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
About Crispr Therapeutics AG
CEOSamarth Kulkarni
Employees393
Founded2013
HeadquartersZug, Zug, Շվեյցարիա
Sector-
Analyst ratings
Based on 13 analysts giving stock ratings to CRSP in the past 3 months
Buy
Buy
8
Hold
5
Sell
0
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for CRSP in the last 3 months.
Highest
Current 51,47 $
110,00 $ (+113,72%)
Average
73,50 $ (+42,80%)
Lowest
45,00 $ (-12,57%)
Analyst
Recommendation
Action
Price target
Projected
Date
Alec Stranahan
Bank of America Securities
Buy
Maintained
81,00 $
+57,4%
10/09/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
80,00 $
+55,4%
10/09/2026
Gil Blum
Needham
Buy
Maintained
82,00 $
+59,3%
10/05/2026
Yanan Zhu
Wells Fargo
Hold
Maintained
75,00 $
+45,7%
10/02/2026
Yigal Nochomovitz
Citi
Buy
Maintained
88,00 $
+71%
09/04/2026
Jonathan Miller
Evercore ISI
Buy
Maintained
76,00 $
+47,7%
08/31/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
08/28/2026
Maxwell Skor
Morgan Stanley
Hold
Maintained
60,00 $
+16,6%
08/28/2026
Salveen Richter
Goldman Sachs
Hold
Reiterated
55,00 $
+6,9%
08/10/2026
Unknown Analyst
Goldman Sachs
Hold
Maintained
55,00 $
+6,9%
08/06/2026
Terence Flynn
Morgan Stanley
Hold
Maintained
60,00 $
+16,6%
08/04/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
110,00 $
+113,7%
08/04/2026
Tyler Van Buren
TD Cowen
Hold
Maintained
45,00 $
-12,6%
08/03/2026
Luca Issi
RBC Capital
Hold
Maintained
50,00 $
-2,9%
08/03/2026
Silvan Turkcan
Citizens JMP
Buy
Maintained
80,00 $
+55,4%
07/22/2026
Unknown Analyst
Mizuho Securities
Buy
Maintained
85,00 $
+65,1%
06/10/2026
William Pickering
Bernstein
Hold
Reiterated
56,00 $
+8,8%
05/13/2026
Geulah Livshits
Chardan Capital
Buy
Reiterated
76,00 $
+47,7%
05/04/2026
Joon Lee
Truist Financial
Buy
Maintained
-
-
03/02/2026
Brian Cheng
J.P. Morgan
Buy
Maintained
67,00 $
+30,2%
02/13/2026
Silvan Tuerkcan
Citizens JMP
Buy
Maintained
80,00 $
+55,4%
01/30/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
889,00 հզր
864,00 հզր
1,46 մլն
10,18 մլն
Cost of goods sold
116,02 մլն
137,23 մլն
114,52 մլն
107,42 մլն
Cost of revenue
116,02 մլն
137,23 մլն
114,52 մլն
107,42 մլն
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
16,93 մլն
18,40 մլն
17,18 մլն
17,55 մլն
Operating expense
16,93 մլն
18,40 մլն
17,18 մլն
17,55 մլն
Total operating expenses
132,95 մլն
155,63 մլն
131,71 մլն
124,98 մլն
Operating income
-132,06 մլն
-154,76 մլն
-130,25 մլն
-114,80 մլն
Other non operating income
26,24 մլն
24,76 մլն
8,16 մլն
27,08 մլն
EBT including unusual items
-105,82 մլն
-130,00 մլն
-122,09 մլն
-90,19 մլն
EBT excluding unusual items
-105,82 մլն
-130,00 մլն
-122,09 մլն
-87,72 մլն
Income tax expense
619,00 հզր
614,00 հզր
839,00 հզր
960,00 հզր
Effective tax rate
-0,58%
-0,47%
-0,69%
-1,06%
Other operating expenses
-
-
-
-
Net income
-106,44 մլն
-130,61 մլն
-122,93 մլն
-91,15 մլն
Net profit margin
-11 973,12%
-15 117,25%
-8 431,48%
-895,33%
Earnings per share
-1,17
-1,37
-1,28
-0,94
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-
Net interest expenses
-
-
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-127,63 մլն
-149,10 մլն
-125,93 մլն
-110,52 մլն
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google Apps